{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:33:30Z","timestamp":1778924010935,"version":"3.51.4"},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,9,28]],"date-time":"2012-09-28T00:00:00Z","timestamp":1348790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Xeroderma pigmentosum (XP) is an orphan autosomal recessive disorder of DNA repair. When exposed to genotoxic stress, XP patients have reduced capacity to remove bulky adducts by nucleotide excision repair and are thus greatly predisposed to cancer. Unfortunately, given the nature of their underlying genetic defect, tumor\u2010bearing XP patients cannot be treated with conventional DNA damaging therapies. Engineered strains of the poxvirus Vaccinia have been shown to cure cancer in numerous preclinical models, and based on promising Phase I\/II clinical trials have recently been approved for late phase evaluation in humans. As poxviruses are nongenotoxic, we investigated whether clinical\u2010candidate strains of Vaccinia can safely and effectively treat cancers arising from XP. <jats:italic>In vitro<\/jats:italic>, Vaccinia virus was highly cytotoxic against tumor\u2010derived cells from XP patients, on average 10\u2010 to 100\u2010fold more so than on nontumor derived control cells from similar patients. <jats:italic>In vivo<\/jats:italic>, local or systemic administration of Vaccinia virus led to durable tumor resolution in both xenograft and genetic models of XP. Importantly, Vaccinia virus was well tolerated in the genetic models, which are each null for a critical component of the DNA repair process. Taken together, our data suggest that oncolytic Vaccinia virus may be a safe and effective therapy for cancers arising from XP, and raise the possibility of similar therapeutic potential against tumors that arise in patients with other DNA repair disorders.<\/jats:p>","DOI":"10.1002\/ijc.27695","type":"journal-article","created":{"date-parts":[[2012,6,26]],"date-time":"2012-06-26T14:29:02Z","timestamp":1340720942000},"page":"726-731","source":"Crossref","is-referenced-by-count":8,"title":["Oncolytic Vaccinia virus safely and effectively treats skin tumors in mouse models of xeroderma pigmentosum"],"prefix":"10.1002","volume":"132","author":[{"given":"Jan","family":"Brun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas J.","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Le Boeuf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cina A.","family":"Sanaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Falls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Andrea","family":"Mccart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F.","family":"Stojdl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,9,28]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0921-8777(99)00047-6"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/35077232"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1987.01660260111026"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1134\/S0006297911010056"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.4.2.169"},{"issue":"1","key":"e_1_2_7_7_2","first-page":"3s","article-title":"Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers","volume":"56","author":"Sinkovics JG","year":"2008","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2007.02.002"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.103"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700066"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90106-O"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2006.05.008"},{"key":"e_1_2_7_13_2","first-page":"8751","article-title":"Systemic cancer therapy with a tumor\u2010selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes","volume":"61","author":"McCart JA","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/377169a0"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/377162a0"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/377165a0"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(92)90051-Z"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.276"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32727"},{"key":"e_1_2_7_20_2","first-page":"1229","article-title":"Establishment and characterization of a melanoma cell line from a xeroderma pigmentosum patient: activation of N\u2010ras at a potential pyrimidine dimer site","volume":"49","author":"Keijzer W","year":"1989","journal-title":"Cancer Res"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300215"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2545"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.55.1.80-122.1991"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70107-4"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.132"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/24.1.139"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.27695","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.27695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T12:16:40Z","timestamp":1697458600000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.27695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,28]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1002\/ijc.27695"],"URL":"https:\/\/doi.org\/10.1002\/ijc.27695","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,28]]}}}